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Objective: Many tumors are poorly immunogenic and resistant to cytotoxic T-
lymphocyte–mediated cell lysis. Because cisplatin has been demonstrated to in-
crease tumor cell Fas receptor expression, we hypothesized that cisplatin will
enhance cytotoxic T-lymphocyte tumor cell killing and augment the antitumor effect
of an active immunotherapy strategy in a poorly immunogenic murine lung cancer
model.
Methods: Lewis lung carcinoma cells were exposed to cisplatin in vitro, and Fas
receptor expression and apoptosis in response to an agonistic anti-Fas antibody were
quantified using flow cytometry. Wild-type and Fas ligand–deficient mice bearing
Lewis lung carcinoma flank tumors were then treated with intraperitoneal cisplatin
as well as an intratumoral injection of an adenovirus gene transfer vector encoding
CD40 ligand. End points included tumor size, animal survival, and Fas expression
(determined using immunofluorescence). Cytotoxicity assays were performed using
splenocytes from adenovirus gene transfer vector encoding CD40 ligand–treated
animals as effectors and cisplatin-treated Lewis lung carcinoma cells as targets.
Results: Cisplatin induced heightened expression of Fas receptor on Lewis lung
carcinoma cells in vitro and in vivo and enhanced apoptosis in cells exposed to an
agonistic anti-Fas antibody. In vivo, the combination of 1 dose of intraperitoneal
cisplatin and intratumoral adenovirus gene transfer vector encoding CD40 ligand
inhibited tumor growth and prolonged survival compared with adenovirus gene
transfer vector encoding CD40 ligand alone, resulting in a higher cure rate. This
effect was lost in Fas ligand–deficient mice. Splenocytes from adenovirus gene
transfer vector encoding CD40 ligand–treated wild-type mice lysed cisplatin-treated
Lewis lung carcinoma cells more efficiently than untreated Lewis lung carcinoma
cells, an effect lost in splenocytes from Fas ligand–deficient mice.
Conclusion: Cisplatin augments the antitumor effect of a cytotoxic T-lymphocyte–
mediated immunotherapy strategy, resulting in a higher cure rate than seen with
immunotherapy alone. This effect is associated with the enhanced ability of cyto-
toxic T lymphocytes to lyse tumor cells that have been exposed to cisplatin through
Fas/Fas ligand interactions.
Lung cancer is the leading cause of cancer mortality in men andwomen in the United States.1 Despite the use of “conventional”antineoplastic therapies (chemotherapy, radiation therapy, and sur-gical resection), fewer than 15% of patients diagnosed with lungcancer will be cured of their disease.1 As most patients die of widelymetastatic disease, there is clearly a need for novel systemic thera-
pies. Active immunotherapy represents a systemic treatment strategy that may be
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potentially useful in many types of malignant disease, in-
cluding lung cancer. By a variety of mechanisms, these
strategies generally focus on enhancing the generation of
cytotoxic T lymphocytes (CTLs), which circulate through-
out the body and specifically induce tumor cell lysis.2-4
Our laboratory has focused on the development of novel
active immunotherapy strategies utilizing in vivo adenovi-
rus (Ad)-mediated gene transfer to induce CTL responses.
In this context, a representative approach has been the direct
transduction of established tumors with an Ad vector en-
coding the CD40 ligand cDNA (AdCD40L), which results
in tumor-specific CTL generation, regression of established
tumors, and long-term protection against tumor rechal-
lenge.5 Although the antitumor effects of AdCD40L are
demonstrable in multiple murine tumor models, they are
less pronounced in the poorly immunogenic Lewis lung
carcinoma (LLC) model, resulting in a negligible long-term
cure rate.5
Cisplatin is a platinum-based, chemotherapeutic agent
that has formed the backbone of systemic therapeutic regi-
mens for both small cell and non–small cell lung cancer
over the last 2 decades.6-8 In addition to its cytotoxic effects,
cisplatin has been shown to enhance expression of the cell
death receptor, Fas, in multiple human tumor cell lines in
vitro, including lung cancer.9-12 Finally, many human lung
cancers are poorly immunogenic and do not express signif-
icant levels of Fas.13-15 Given this information, as well as
the limited antitumor effect of AdCD40L in the poorly
immunogenic LLC model, we hypothesized that cisplatin
may enhance the antitumor immunity evoked by AdCD40L
in this model and that this enhancement would be due to
heightened ability of tumor-specific CTLs to induce killing
of LLC. In this regard, the data demonstrate: (1) exposure of
LLC cells to cisplatin increases Fas expression in vitro and
the up-regulated Fas serves as a functional cell death recep-
tor; (2) 1 dose of intraperitoneal cisplatin induces intense
Fas expression by established LLC tumors in syngeneic
mice, an effect that lasts for at least 3 days; (3) the addition
of 1 dose of intraperitoneal cisplatin to the administration of
AdCD40L into established LLC tumors results in enhanced
tumor regression and long-term survival when compared
with the vector alone; (4) splenocytes from AdCD40L-
treated mice lyse cisplatin-exposed LLC cells more effi-
ciently than naı¨ve LLC cells; and (5) these enhanced anti-
tumor effects of cisplatin are completely abrogated in Fas
ligand–deficient mice.
Materials and Methods
Mice
Six- to eight-week-old female wild-type C57BL/6 (H-2d) and Fas
ligand–deficient C57BL/6 (B6Smn.CH3-Tnfsf6gld) mice were ob-
tained from Jackson Laboratories (Bar Harbor, Me). The mice
were housed under specific pathogen-free conditions and treated
according to the National Institutes of Health guidelines. The Fas
ligand / phenotype was confirmed by flow cytometric analysis
of splenocytes (not shown). All animal procedures were approved
by the Institutional Animal Care and Use Committee.
Cell Culture
Lewis lung carcinoma (H-2d; a murine lung carcinoma) and
B16.F10 (H-2d; a murine melanoma) are both syngeneic to
C57BL/6 (H-2d) mice. The cell lines were obtained from American
Type Culture Collection (ATCC; Manassas, Va) and maintained in
complete Dulbecco’s modified Eagle’s medium (DMEM; 10%
fetal bovine serum, 100 g/mL streptomycin, and 100 U/mL
penicillin) at 5% CO2 and 37°C.
Adenovirus Vectors
All gene transfer vectors used in this study are replication-defi-
cient, E1-, E3- vectors based on the adenovirus serotype 5 (Ad5)
genome. AdCD40L contains an expression cassette with the mu-
rine CD40L cDNA driven by the cytomegalovirus (CMV) early-
immediate promoter/enhancer.5 AdNull, a control vector, is similar
but contains no transgene.16 Ad vectors were propagated in human
embryonic kidney cells (293 cells; ATCC) and purified through 2
cesium chloride gradient ultracentrifugations as previously de-
scribed.17,18 The viral particle concentration was determined by
ultraviolet absorbance at 260 nm.19
Quantification of Fas Receptor Expression and Fas-
mediated Apoptosis in Vitro
To demonstrate the ability of cisplatin to up-regulate Fas receptor
in LLC cells in vitro, nearly confluent LLC cells were exposed to
either 2.5 g/mL or 5.0 g/mL of cisplatin (Sigma Chemical Co,
St Louis, Mo) for 3 hours in complete DMEM at 37°C. The cells
were washed 3 times with phosphate-buffered saline (PBS) and
cultured in complete DMEM for an additional 36 hours. Sham-
treated LLC cells served as controls. The cells were then stained
with a phycoerthythrin (PE)-conjugated rat anti-murine Fas mono-
clonal antibody (mAb; Pharmingen, San Diego, Calif) or the
appropriate isotype-matched, PE-conjugated control mAb (Pharm-
ingen) and subjected to flow cytometric analysis (FACSCalibur;
Becton Dickinson, San Jose, Calif).
To assess the functional activity of the up-regulated Fas recep-
tor, LLC cells were cultured in complete DMEM containing 5
g/mL of cisplatin for 3 hours. The cells were then washed 3 times
with PBS and cultured in complete DMEM at 37°C. After 24
hours, 1 g/mL of an agonistic rat anti-mouse Fas mAb (Jo2;
Pharmingen) was added to the media and incubated for an addi-
tional 24 hours at 37°C. The cells were washed 3 times with PBS
and stained with fluoroisothiocyanate (FITC)-conjugated annexin
V (R&D Systems, Minneapolis, Minn) and TO-PRO-3 iodide
(Molecular Probes, Eugene, Ore) for 15 minutes at 23°C. The cells
were then subjected to flow cytometric analysis (FACSCalibur).
Immunofluorescence
To assess the ability of cisplatin to enhance Fas expression on
established tumors in vivo, 5  105 LLC cells were injected
subcutaneously in the right flanks of wild-type C57BL/6 mice.
When the tumors were approximately 45 to 50 mm2 in size (day 8),
7 mg/kg of cisplatin was administered as a single intraperitoneal
dose. The animals were sacrificed and the tumors harvested 24 and
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72 hours after cisplatin injection. Sham-treated tumor-bearing
mice served as controls. Tumors were snap-frozen in liquid nitro-
gen, cut into 10-m sections, and fixed in cold acetone. After
blocking nonspecific staining with normal goat serum, the samples
were treated with rabbit anti-mouse Fas receptor mAb (Santa Cruz
Biotech, Santa Cruz, Calif) in 5% goat serum for 2 hours. The
samples were then incubated with an FITC-labeled goat anti-rabbit
IgG (Santa Cruz Biotech) for 1 hour in 5% normal goat serum,
followed by 5 minutes in 4',6-diamidino-2-phenylindole (1 g/
mL; Molecular Probes) in 0.1% Triton X-100 to stain nuclei (to
verify the presence of intact cells on the slides). The sections were
then assessed using fluorescence microscopy.
Ability of Tumor-specific CTLs to Lyse LLC Cells
To demonstrate the effect of cisplatin on the ability of AdCD40L-
induced CTLs to lyse LLC cells, LLC tumors were initiated in the
flanks of wild-type C57BL/6 mice as described above. When the
tumors reached approximately 45 to 50 mm2 in size (day 8),
AdCD40L or AdNull was administered intratumorally in 100 L
PBS (5  1010 particles). Untreated animals served as further
controls. Ten days after vector administration, spleens were har-
vested and minced and the red blood cells lysed using ACK buffer
(Biosource International, Camarillo, Calif). Splenocytes from 3
animals in each group were pooled, and 8  106 splenocytes were
restimulated with 2  106 mitomycin C–treated LLC cells (100
g/mL mitomycin C for 90 minutes; Sigma) for 5 days (4 mL of
complete RPMI-1640). After restimulation, viable effector cells
(splenocytes) at varying effector-to-target ratios (6:1, 20:1, 100:1)
were analyzed in a standard 51Cr-release assay for their ability to
lyse 51Cr-labeled target cells during a 6-hour incubation at 37°C.
Target cells included untreated LLC cells, cisplatin-treated LLC
cells, and untreated syngeneic control B16.F10 cells (2  104/200
L/well) The percentage of specific 51Cr-release was calculated as
([experimental release spontaneous release]/[maximal release
spontaneous release])  100. To establish the role of Fas/Fas
ligand interactions on the target cell killing ability of AdCD40L-
induced CTLs, the same experiment was conducted using spleno-
cytes obtained from tumor-bearing, Fas ligand–deficient mice
(B6Smn.CH3-Tnfsf6gld) after vector treatment.
Evaluation of the Effect of Cisplatin Administration
on the Antitumor Properties of AdCD40L in Vivo
LLC flank tumors were initiated as described above in wild-type
C57BL/6 mice. When the tumors reached approximately 45 to 50
mm2 in size (day 8), AdCD40L or AdNull was administered
intratumorally in 100 L PBS (5  1010 particles). Cisplatin (7
mg/kg) was administered as a single intraperitoneal dose concom-
itantly with vector injection. The size of the flank tumor was
assessed in situ every 2 to 3 days by measuring the largest
perpendicular diameters using microcalipers and recorded as an
average tumor area (mm2). When the animals appeared moribund
or the tumor growth exceeded 15 mm in the largest diameter, the
mice were killed, and this time point was defined as death for
survival analysis. Untreated animals served as further controls. To
assess the role of Fas/Fas ligand interactions in the effect of
cisplatin on tumor immunity, the same experiment was conducted
in Fas ligand–deficient mice (B6Smn.CH3-Tnfsf6gld).
Statistical Analysis
All data are reported as mean  standard error. Statistical signif-
icance between the means was determined using the unpaired,
2-tailed Student t test. Survival evaluation was performed using the
Kaplan-Meier analysis (P value determined by log-rank test).
Results
Exposure of Lewis Lung Carcinoma to Cisplatin
Increases Expression of Fas Receptor in Vitro and in
Vivo
The effect of cisplatin on the surface expression of Fas
receptor was evaluated by exposing LLC cells to 2 different
doses of cisplatin for 3 hours in culture and evaluating the
cells using flow cytometry. LLC cells exposed to 2 g/mL
of cisplatin displayed heightened expression of Fas receptor
compared with cisplatin-treated cells stained with an iso-
type-matched control mAb (not shown) or untreated cells
(Figure 1, A). When the dose of cisplatin was increased to 5
g/mL, only a minimal increase was demonstrated over the
lower dose (Figure 1, B). To determine if this up-regulation
could be demonstrated in vivo, LLC tumors were initiated in
the flanks of syngeneic, wild-type mice and 1 intraperitoneal
dose of cisplatin (7 mg/kg) was administered after the
tumors were established. Tumors were harvested 24 and 72
hours after cisplatin dosing and evaluated for Fas expression
using immunofluorescence. Although sham-treated tumors
expressed negligible Fas receptor (Figure 2, A and B),
tumors from animals treated with cisplatin uniformly ex-
pressed Fas 24 hours after dosing (Figure 2, C and D), an
effect that was preserved for at least 72 hours (Figure 2, E
and F). No expression was detected in any tumors stained
with the isotype-matched control Ab (not shown).
Up-regulated Fas on LLC Cells Is a Functional
Receptor for Apoptosis
Because cisplatin enhances Fas expression both in vitro and
in vivo, experiments were conducted to determine if this
up-regulated receptor would initiate apoptosis of the LLC
cells upon ligation. LLC cells were exposed to 5 g/mL
cisplatin in vitro for 3 hours; 24 hours later, apoptosis was
assessed using annexin staining and flow cytometry. Al-
though sham-treated LLC cells in culture contained some
dead cells (Figure 3, A, upper 2 quadrants), cells undergoing
apoptosis were not detected (lower, right quadrant). Expo-
sure of LLC cells to the agonistic anti-Fas mAb (Jo2) had no
effect on apoptosis (Figure 3, B). Cisplatin exposure alone
enhanced apoptosis in LLC cells (Figure 3, C), but this
effect was markedly potentiated by the addition of the
agonistic anti-Fas mAb (Figure 3, D).
CTLs from AdCD40L-treated, Tumor-bearing Mice
Lyse Cisplatin-treated LLC Cells More Efficiently
Than Untreated LLC Cells
To determine whether the tumor-specific CTLs induced by
AdCD40L will lyse LLC cells more efficiently if they have
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been exposed to cisplatin, splenocytes from wild-type mice
receiving an intratumoral injection of AdCD40L were iso-
lated, restimulated in vitro, and evaluated in standard cyto-
toxicity assays. During a 6-hour incubation, splenocytes
from AdCD40L-treated mice lysed LLC cells more effec-
tively than untreated LLC cells (Figure 4, A and B). How-
ever, these splenocytes were unable to lyse the syngeneic,
control cell line, B16.F10 (Figure 4, C). Similarly, there was
no lysis noted when splenocytes from either AdNull-treated
or untreated tumor-bearing mice were incubated with any
target cell (Figure 4, A, B, and C).
To evaluate the role of Fas/Fas ligand interactions in the
ability of these tumor-specific CTLs to lyse target cells, the
same experiment was repeated in Fas ligand–deficient mice.
Splenocytes from these mice were unable to lyse either LLC
cells or B16.F10 cells, regardless of cisplatin treatment
(Figure 4, D, E, and F).
Addition of Cisplatin to a CTL-inducing
Immunotherapy Strategy in Vivo Enhances Tumor
Regression and Prolongs Survival
To evaluate whether the addition of cisplatin enhances the
antitumor effect of AdCD40L in vivo, LLC tumor-bearing
wild-type C57BL/6 mice were given intratumoral
AdCD40L as well as intraperitoneal cisplatin (1 dose of
each), and tumor size was assessed over time. Tumor re-
gression was more pronounced in the animals that received
cisplatin plus AdCD40L (Figure 5, A) compared with that
seen in the mice receiving AdCD40L alone (P  .04),
AdNull alone (P  .002), cisplatin alone (P  .00009),
AdNull plus cisplatin (P  .0002), or no therapy (P 
.000003). To establish the role of Fas/Fas ligand interac-
tions in this antitumor effect, the same experiment was
repeated in Fas ligand–deficient mice. Strikingly, the ability
of cisplatin to enhance the antitumor effect of AdCD40L
was abrogated in these transgenic mice (Figure 5, B; P .2;
AdCD40L plus cisplatin versus AdCD40L alone).
Because intratumoral AdCD40L alone results in a min-
imal cure rate when administered to established LLC tumors
in syngeneic mice, animals were followed with survival as
the end point. In wild-type C57BL/6 mice, significantly
more animals receiving the combination of AdCD40L and
cisplatin were cured of their tumors than those receiving the
vector alone (Figure 6, A; 43% versus 14%; P  .03). In
contrast, no Fas ligand–deficient animals were cured of
their tumors, regardless of treatment (Figure 6, B).
Discussion
Although innate antitumor immune responses exist, adap-
tive, specific tumor immunity is generally thought to be a
cellular process, mediated by CD8 CTLs as the immune
effector cells.2-4 Activated CTLs are thought to induce cell
death in target tumor cells mainly by the perforin/granzyme
pathway, a process that requires direct cellular contact and
target cell recognition via major histocompatibility complex
class I.3,4,20 However, activated CTLs also express Fas
ligand, which may bind to and induce apoptosis in tumor
cell targets if the tumor expresses the Fas receptor.3,4,20
Lack of Fas expression by tumors may represent 1 mecha-
Figure 1. Exposure of LLC cells to cisplatin in vitro increases
expression of Fas receptor. LLC cells were exposed to cisplatin at
2 different doses for 3 hours; 36 hours after exposure, the cells
were stained with either a PE-conjugated rat anti-mouse Fas
receptor mAb or an appropriate isotype-matched control mAb and
subjected to flow cytometry. Sham-treated cells served as con-
trols. The results are representative of 3 independent experi-
ments. A, LLC cells treated with 2.0 g/mL of cisplatin. B, LLC
cells treated with 5.0 g/mL of cisplatin. No staining was seen in
the isotype-matched control groups (not shown).
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nism by which tumors can evade CTL-mediated immune
responses. For example, Fas receptor expression is absent or
reduced in human lung cancers, affecting the susceptibility
of these tumors to Fas-mediated apoptosis.14
Given the activity of cisplatin-based chemotherapeutic
regimens in small cell and non–small cell lung cancer and
the observation that cisplatin increases Fas receptor expres-
sion on multiple tumor cell lines in vitro, the present study
was designed to determine whether cisplatin will enhance
the antitumor effect of a CTL-inducing immunotherapy
strategy based on its ability to up-regulate Fas expression on
tumors. The data show that cisplatin markedly increases Fas
expression in a poorly immunogenic, syngeneic murine
lung cancer in vitro and in vivo and that this up-regulated
Fas is a functional apoptosis receptor. In addition, tumor-
specific CTLs are able to lyse cisplatin-treated LLC cells
Figure 2. Intraperitoneal administration of cisplatin increases expression of Fas receptor in established LLC flank
tumors. Tumors were initiated in syngeneic, wild-type mice and cisplatin was administered as a single intraperi-
toneal dose 8 days later; 24 and 72 hours after cisplatin treatment (7 mg/kg), the tumors were harvested,
snap-frozen, and evaluated using immunofluorescence. Controls consisted of sham-treated mice as well as
isotype-matched control mAb used in the staining protocol. Green fluorescence indicates Fas expression. A, Sham
treatment. B, Nuclear staining from section in A. C, Twenty-four hours after cisplatin dosing. D, Nuclear staining
from section in C. E, Seventy-two hours after cisplatin dosing. F, Nuclear staining from section in E. No green
fluorescence was demonstrable in any sections exposed to the isotype-matched control mAb.
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more effectively than untreated LLC cells, which translates
into more pronounced tumor regression and better cure rate
when cisplatin is combined with an active immunotherapy
strategy in vivo.
Cisplatin Enhances Tumor Cell Killing by AdCD40L-
generated CTLs via Fas/Fas Ligand Interactions
The susceptibility of tumors to active immunotherapy strat-
egies is dependent on both the generation of CTLs and the
ability of CTLs, once activated, to induce apoptosis in the
tumor cells.2-4 LLC is a murine tumor refractory to active
immunotherapy compared with other syngeneic murine tu-
mors, exemplified by the consistent lack of long-term cures
in mice bearing LLC tumors treated with immunothera-
pies.5,21 As a result, LLC represents an appropriate model in
which to evaluate the effect of cisplatin.
The present study suggests that cisplatin augments the
ability of tumor-specific CTLs to induce Fas ligand–medi-
ated apoptosis of LLC cells, resulting in more pronounced
tumor regression in a flank tumor model. This is supported
by several observations. First, LLC cells express little Fas
receptor, which is intensely up-regulated by the addition of
cisplatin in vitro and in vivo. Although the in vitro concen-
trations of cisplatin probably do not represent in vivo phys-
iologic concentrations of this agent, the in vivo data clearly
show that Fas receptor is up-regulated at a dose that does
not induce toxicity or tumor regression (a “subtherapeutic”
dose). Second, CTLs from AdCD40L-treated wild-type
mice lyse LLC cells more effectively if the LLC cells have
been exposed to cisplatin. Finally, complete abrogation of
this enhanced cell lysis occurs in Fas ligand–deficient mice.
Interestingly, CTLs from Fas ligand–deficient mice pos-
Figure 3. The Fas receptor up-regulated by cisplatin is a functional apoptosis receptor. LLC cells were exposed
to cisplatin (5 g/mL) for 3 hours followed by incubation for 24 hours with an agonistic anti-Fas mAb (Jo2; 1 mg/mL).
The cells were washed with PBS, stained with FITC-conjugated annexin V as well as To-PRO-3-iodide, and
subjected to 2-color flow cytometry. Shown is a representative experiment of 3 individual studies. Dead cells are
depicted in the upper 2 quadrants, and cells undergoing apoptosis are depicted in the lower right quadrant. A,
Untreated LLC cells. B, LLC cells exposed to Jo2 mAb alone. C, LLC cells exposed to cisplatin alone. D, LLC cells
exposed to cisplatin and Jo2 mAb.
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sessed no ability to lyse LLC in any of the groups, implying
that the major mechanism of apoptosis induction by CTLs
generated via AdCD40L is the Fas/Fas ligand pathway, as
opposed to the perforin/granzyme pathway. This finding is
consistent with other published data showing CTLs can
induce tumor cell apoptosis in the absence of perforin.22
Immunohistochemical analysis of human lung cancer has
revealed Fas expression in only 30 to 50% of tumors.15 In
addition, lung cancer patients with Fas-expressing tumors
have been demonstrated to have significantly longer median
survival than patients with Fas-negative tumors,14 and ap-
optosis induced by an agonistic anti-Fas antibody has been
shown to correlate with the degree of Fas expression in
human lung cancer cell lines.13 Finally, up-regulation of Fas
receptor on human tumor cell lines has resulted in accentu-
ated Fas-mediated cytotoxicity by allogeneic peripheral
blood lymphocytes.9 These data, combined with the data in
the present study, suggest that up-regulation of Fas receptor
by cisplatin may be of benefit when used in conjunction
with active immunotherapy in patients with lung cancer.
Clinical Implications of Cisplatin Combined With
AdCD40L
Because lung cancer is associated with poor survival, with
most patients dying of disseminated disease, active immu-
notherapy warrants investigation as a novel therapeutic
strategy. However, tumor-associated antigens are poorly
characterized and heterogenously expressed in human
lung cancers, making antigen-specific vaccination strat-
egies problematic. AdCD40L is a strategy that does not
require prior knowledge of specific tumor antigens and,
as such, may represent a valid approach for this disease.
Because cisplatin is an established drug in the treatment
of lung cancer, the finding that it also augments the
antitumor effect of a CTL-mediated immunotherapy
strategy is highly relevant for clinical application. A
potential drawback of this approach is that the ability of
chemotherapeutics to enhance Fas receptor expression in
some cell lines requires the presence of wild-type p53,12
although human non–small cell lung cancer is associated
with p53 mutations in approximately 50% of cases.
Figure 4. CTLs from tumor-bearing, wild-type C57BL/6 mice are more effective at lysing LLC cells exposed to
cisplatin than untreated LLC cells, an effect abrogated in Fas ligand– deficient mice. Ten days following injection
of either AdCD40L and AdNull (5  1010 particles in 100 L) into established LLC tumors, splenocytes were
harvested, restimulated with mitomycin C–treated LLC cells for 5 days in vitro, and evaluated for cytotoxicity
against target LLC cells or cisplatin-treated target LLC cells in a standard 51Cr release assay. B16.F10 cells were
used as a control target cell line. Untreated LLC tumor-bearing mice served as further controls. Data points
represent the mean SEM of 5 wells for each group. Shown is a representative experiment of 3 individual studies,
all with similar results. A, Wild-type splenocytes, LLC target cells treated with cisplatin (5 g/mL). B, Wild-type
splenocytes, untreated LLC target cells. C, Wild-type splenocytes, B16.F10 target cells. D, Fas ligand– deficient
splenocytes, LLC target cells treated with cisplatin (5 g/mL). E, Fas ligand– deficient splenocytes, untreated LLC
target cells. F, Fas ligand– deficient splenocytes, B16.F10 target cells.
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Whether cisplatin will augment the antitumor activity of
AdCD40L in tumors with mutated p53 remains to be
determined.
We thank N. Mohamed for help in preparing this manuscript.
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